Methods of treating cancer

A method of treating cancer in a patient who has been receiving a multimodal cancer immunotherapy for at least two months, the method comprising:

• a. calculating T cell receptor (TCR) diversity in a blood sample from the cancer patient before initiation of the multimodal cancer immunotherapy, or at initiation of the multimodal cancer immunotherapy;
• b. calculating the TCR diversity in a blood sample from the cancer patient at least two months after initiation of the multimodal cancer immunotherapy to the patient;
• c. comparing the TCR diversity from steps a and b;
• and
• d. continuing administration of the multimodal cancer immunotherapy to the patient, if the T cell receptor (TCR) diversity in the blood sample from the patient increases at least three-fold between steps a and b;
• wherein
• the multimodal cancer immunotherapy comprises an NK cell selected from the group consisting of aNK, haNK, taNK, and t-haNK;
• or
• the multimodal cancer immunotherapy comprises two or more immunotherapies selected from the group consisting of a viral vector expressing an antigen, a yeast immunotherapy, an immune checkpoint inhibitor, and an IL-15 superagonist.